Blood Transfusion Clinical Trial
— IMOTECOfficial title:
Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery Using Conventional Blood Coagulation Tests or Thrombo-elastographic Point of Care Test - IMOTEC
NCT number | NCT02972684 |
Other study ID # | RC16_0009 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 3, 2017 |
Est. completion date | February 2020 |
Verified date | February 2020 |
Source | Nantes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Peri operative haemorrhage following cardio Pulmonary Bypass may occur in 5 to 10% of cardiac
surgical interventions.
Treatment of such complication often necessitates various combinations therapeutic
intervention including allogenic blood products administration, drug use and/or surgical
intervention. All are expensive treatment and decision making is guided by patient clinical
status and biological tests of the haemostatic function.
A key point is the time frame of the clinical process. Therapeutic choices have to be done as
fast as possible to minimize bleeding consequences on patient haemodynamic and physiological
status. Conventional coagulation test results availability time usually exceed 45' after
blood drawing. In such situation, the results may not reflect precisely the coagulation
system current state. This downside is often counterbalanced by clinicians empirical choices
preceding lab test results knowledge that may conduct to inappropriate treatment, blood
product overuse and undue expense.
Viscoelastic point of care test may compensate for the limitations of conventional
coagulation tests. In perioperative haemorrhage, faster and more precise information about
haemostatic function may help for more accurate therapeutic choices.
The IMOTEC study aims to compare haemorrhage management following cardiac surgery using
conventional blood coagulation tests or thrombo-elastogaphic point of care test.
Primary endpoint is a cost utility analysis of the technology and secondary endpoints include
blood component transfusion, postoperative bleeding , thoracic re-intervention, postoperative
infection (any cause), organ failure, in hospital length of stay and death.
Status | Completed |
Enrollment | 1098 |
Est. completion date | February 2020 |
Est. primary completion date | February 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Pre-Inclusion Criteria: - Adult patients over 18 years old scheduled for elective or urgent cardiac surgery using cardiopulmonary bypass . - Patient informed written consent (non-opposition to data use) or person of trust or family member information . Inclusion Criteria: Blood Coagulation test sampling indication for intra or post-operative bleeding defined as follow: 1. intra-operative post CPB bleeding; evaluation more than 10min after heparin reversal by protamin. - Clinically significant bleeding judged on surgeon and anesthesiologist consensual point of view - Sternal closure delay - Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h) 2. Postoperative period , evaluation in post operative care environment after 30min stabilization period - Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h) - Patient requiring surgical re-exploration for diagnosed or suspected pericardial effusion or surgical site bleeding requiring surgical hemostatic intervention Exclusion Criteria: - Known congenital bleeding disorder - Redo surgery for patient previously included in the study - Implantation of Cardiac support device, Extra Corporeal Membrane Oxygenation (ECMO) Extra Corporeal Life support (ECLS), uni or bi-ventricular artificial hearts. - Indication for post-CPB ECMO or ECLS - blood transfusion refusal - pregnant women - patients under 18 years old - Adult patient under guardianship, trusteeship or safeguard justice |
Country | Name | City | State |
---|---|---|---|
France | Angers University Hospital | Angers | |
France | Bordeaux University hospital | Bordeaux | |
France | Caen University Hospital | Caen | |
France | Clermont-Ferrand University Hospital | Clermont-Ferrand | |
France | Dijon University Hospital | Dijon | |
France | Lille University hospital | Lille | |
France | Marseille AP-HM La Timone | Marseille | |
France | Nancy University Hospital | Nancy | |
France | APHP, La Pitié Salpétrière | Paris | |
France | HEGP, Hôpital Européen Georges Pompidou | Paris | |
France | Rouen University Hospital | Rouen | |
France | Saint-Etienne University Hospital | Saint-Etienne | |
France | Strasbourg Universtiy Hospital | Strasbourg | |
France | Toulouse University Hospital | Toulouse | |
France | Tours University Hospital | Tours |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital | Ministry of Health, France |
France,
Rigal JC, Boissier E, Lakhal K, Riche VP, Durand-Zaleski I, Rozec B. Cost-effectiveness of point-of-care viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study with stepped-wedge cluster randomised controlled design and 1-year follow-up (the IMOTEC study). BMJ Open. 2019 Nov 5;9(11):e029751. doi: 10.1136/bmjopen-2019-029751. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cost-utility ratio | incremental cost per incremental life year and incremental costs per incremental QALY | one year | |
Secondary | incremental cost effectiveness ratio | incremental cost effectiveness ratio : difference in costs divided by the difference in mortality and serious adverse events | one year | |
Secondary | Complication rates | Parameters followed during hospitalization are: volume of postoperative bleeding, allogeneic blood product transfusion, blood cell count, postoperative complications: surgical reexploration, acute kidney injury, need for renal replacement therapy, organ failure, acquired infections, mechanical ventilation duration, intensive care, and in hospital length of stay, death. | one year | |
Secondary | Complication rates | The major complications that can occur within 12 months are: death, cardio-thoracic surgical intervention, acute kidney injury, need for renal replacement therapy, any serious illness diagnosis. | one year | |
Secondary | Evaluation survey | Evaluation survey regarding the context and the parameters that impacted the physician's decision, which will be used a sub-group of 100 patients. | Day 1 | |
Secondary | The location of the Thrombo-elastometry POC testing | The location of the Thrombo-elastometry POC testing (operative room or laboratory) | three years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03651154 -
Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections
|
N/A | |
Completed |
NCT01136590 -
Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery
|
Phase 4 | |
Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
Completed |
NCT00005303 -
Effectiveness of AIDS Antibody Screening
|
N/A | |
Completed |
NCT00005319 -
Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine
|
N/A | |
Completed |
NCT00005301 -
Transfusion Safety Study (TSS)
|
N/A | |
Completed |
NCT00000581 -
Granulocyte Transfusion Study
|
Phase 3 | |
Completed |
NCT04089865 -
Oral Versus Intravenous Tranexamic Acid
|
Phase 4 | |
Completed |
NCT02968654 -
TRansfusion Strategies in Acute Brain INjured Patients
|
N/A | |
Enrolling by invitation |
NCT06019364 -
Transfusion of Whole Blood in Acute Bleeding
|
||
Completed |
NCT04911413 -
Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery
|
Phase 4 | |
Completed |
NCT03727230 -
RhD+ Blood Transfusion to Asian-type DEL Recipients
|
N/A | |
Recruiting |
NCT06102590 -
Oxygen Extraction-guided Transfusion
|
N/A | |
Completed |
NCT00400192 -
Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury
|
N/A | |
Completed |
NCT00000593 -
Viral Activation Transfusion Study (VATS)
|
N/A | |
Completed |
NCT05627544 -
Blood Transfusion Applications in Hip Replacements
|
||
Completed |
NCT05581238 -
Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.
|
||
Not yet recruiting |
NCT03429790 -
Cell Salvage During Caesarean Section (CSCS)
|
N/A | |
Completed |
NCT00822588 -
Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not
|
N/A | |
Withdrawn |
NCT00269971 -
A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.
|
Phase 3 |